Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript

Evaxion Biotech A/S (NASDAQ:EVAX) Q4 2024 Earnings Call Transcript April 1, 2025

Evaxion Biotech A/S misses on earnings expectations. Reported EPS is $-0.07 EPS, expectations were $-0.03.

Operator: Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast. At this time, all participants will be in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please note that today’s conference is being recorded. I would now like to hand the conference over to your speaker, Christian Kanstrup, CEO. Please go ahead.

Christian Kanstrup: Thank you so much, and good morning and good afternoon to all of you, and a very warm welcome to this Evaxion full year 2024 business update call. I’m Christian Kanstrup, CEO of Evaxion. With me today, I have Birgitte Rønø, our Chief Science Officer; Thomas Schmidt, our Chief Financial Officer; and Mads Kronborg, our VP of Investor Relations and Communications. I think it’s fair to say that 2024 was a super exciting year for Evaxion with lots of achievements throughout the year, and we are looking very much forward to be giving you an update on the year. And the agenda and what we intend to cover. First of all, I will start out recapping on 2024, looking ahead into 2025 and some of the significant milestones that we see in front of us.

Birgitte will be taking us through the R&D update. Thomas will cover the 2024 financial results. And I will be having a few conclusive remarks before we, as usual, jump into the Q&A. And another thing that is as usual is the forward-looking statements. We will be talking about the future. And of course, talking about the future entails uncertainties. Hence, I direct your attention to the forward-looking statements slide on Slide #3. And with that, let’s get into the agenda and start out with recapping on ’24 and looking ahead. First of all, as I already said, I think it’s fair to say 2024 was a year of substantial progress across Evaxion. That goes for all parts of the business; if we look at business development, if we look at R&D, if we look at our platform and also when we look at financing.

I’m truly proud of what the team and the whole organization has achieved throughout the year. I think it’s also fair to say that it has provided us with a very strong foundation going into 2025. But if we start out looking at business development here, of course, we entered into the transformational partnership with MSD in September 2024, a very important achievement for the year. And I’m also happy to say that we are tracking well towards potential option exercise in the second half of 2025. Brigitte will also be getting back to this. Also, I’m pleased to say that our current business development pipeline supports our ambition of at least two new agreements. Just to recap, we have a very strong focus on partnering as a way of realizing value of both our platform and pipeline and, of course, maintaining a business development pipeline, which can generate future partnerships is important to us.

From an R&D point of view, we have continued the successful execution of the ongoing EVX-01 Phase 2 trial. We presented convincing one-year data in the fall of last year, 69% overall response rate at the one-year readout of the ongoing Phase 2 trial and 15 out of 16 patients showing a reduction in tumor target lesions. Truly exciting data, which makes us look very much forward to the two-year readout that we will be having in the second half of the year. What we have also done is established a completely new precision cancer vaccine concept deploying our AI-Immunology platform, targeting non-conventional endogenous retroviruses tumor antigens, which are shared across patients. This is exciting because it broadens the potential of cancer vaccines and a precision-based approach is a very nice complement to our personalized cancer vaccine, EVX-01, which has complemented nicely.

Looking at the platform, AI-Immunology, it’s a core of our business and, of course, ensuring ongoing development and performance improvement of the platform is critical for staying off the forefront of AI-derived development of novel medicines. And here, I’m very pleased that we last year launched a novel toxin antigen predictor, which allows us for developing even better bacterial vaccines. This continuous improvement of the both capabilities and the performance of AI-Immunology remains a priority to us. Last but not least, financing is, of course, a important factor in our business. And here, I’m pleased to say that we, by our public offering and other capital market activities, have extended our cash at hand to mid-2026. In addition to that, Merck or MSD Global Health Innovation Fund have invested in us for the third time, now holding a close to 20% equity stake.

We are very pleased about the strong relationship we have with the Merck or MSD Global Health Innovation Fund, and are pleased to see the continued and ongoing support and, of course, welcome them as a significant shareholder in Evaxion. If we then turn to the next slide and look ahead, we have quite significant value triggers coming up throughout the year. I’m also pleased to say that we already delivered on our first milestone for the year, which is the all patients completing dosing in the EVX-01 trial. But we also will be presenting later on this month actually at the AACR meeting is additional EVX-01 data. Looking into the second half, a number of significant milestones here. The MSD vaccine collaboration and the decision on option exercise is expected in the second half could generate up to $10 million in income to Evaxion if MSD exercises the options to both.

Needless to say, a very important milestone for us. And also, as I already mentioned, pleased to see that the collaboration is on track. Then, we will have the two-year readout on EVX-01 in the second half of the year as well. With a strong one-year readout, we are very much looking forward to that. We will be selecting lead antigens for our CMV vaccine candidate, which now is a fully-owned candidate, which we also are looking forward to. And then, building on the precision vaccine concept — or comments I had just before, we will be selecting lead vaccine candidate in the second half as well. Throughout the year, two other significant milestones: business development, we have the ambition of generating at least two new agreements in 2025 and are working hard towards that; and continuing building our pipeline is also a priority with a multi-partner approach, partnering around existing pipeline candidates just as we included the EVX-B2 in the collaboration with MSD, then we need to continue building the pipeline with novel candidates in order to ensure that we have a attractive and broad pipeline of novel vaccine candidates, which we can partner via our multi-partner approach.

Here we have the target of two new pipeline candidates within infectious diseases, one in the first half and one in the second half. Also here, pleased to say that we are well on track towards meeting that. Just a very quick recap on our focus. Our focus is on deriving value from both our platform and our pipeline. And the unique nature here is the complementarity of having a dual focus on platform and pipeline, which is driven by the unique capabilities and properties of AI-Immunology and the multidisciplinary capabilities that we have built around our AI-Immunology platform. Focus of the platform that is to enter into high-value, low-risk partnerships around target discovery, design and development of novel vaccine candidates. The MSD collaboration around EVX-B3 is a good example of that.

And then, it’s, of course, also deploying the platform to expand and build our own pipeline, just as we have the target of these two new infectious disease candidates for the year; pipeline that is around advancing select high-value programs into preclinical and early clinical development, leveraging our multidisciplinary capability base and then pursue partnering at the right point in time. The partnering with MSD around EVX-B2 is a good example of what we want to do here. And of course, we have EVX-01 in Phase 2 development and very much looking forward to the clinical data readout later on this year. So, focusing on both platform and pipeline, but being able to do so in a cost-effective way via the unique features of the AI-Immunology platform and the multidisciplinary capabilities we have around that.

We are confident that this strategy will generate significant opportunities going forward and are executing in full focus on that. And then, before handing over to Birgitte, I would just touch a little bit on a few recent events. In January, we completed a public offering and together with other capital market activities, we have raised US$17 million this year, extending our cash runway to mid-2026. As already mentioned, MSD, Global Health Innovation Fund, participated in the offering, but what I’m also very pleased around is to see other healthcare-focused investors in the public offering. With that offering, we have had a very nice expansion of our investor base and looking forward to continuing the collaboration with those investors we got in, in that round.

We have also communicated that we are in agreement and discussions with the European Investment Bank around conversion of €3.5 million out of the €7 million loan we have with EIB into an equity-type instrument. Originally, we had communicated we expected that completed in the first quarter. We can see that some of the legal documentations takes longer to complete than anticipated, but now we are expecting to complete this in the second quarter. This will enable a significant simplification of our balance sheet and also save cost in terms of interest payments going forward. So, we are looking forward to having that loan conversion converted into equity. We, in 2024, got a delisting determination from Nasdaq. We are very pleased to say that has been withdrawn here in the first quarter.

We are now in full compliance with all Nasdaq listing requirements. Another thing that makes me proud and happy is the ongoing efforts in the whole organization in terms of optimizing our spend. And that has enabled us to have a 2025 operational cash burn at US$14 million, which is the same level as 2024 despite an increased activity level. And this ongoing spend optimization is, of course, important because it allows us to do more while still being very cautious in how we spend our cash. Finally, also for the first quarter, EVX-01 completed dosing. I already mentioned that. What we also have announced is that we have extended the EVX-01 trial from two to three years. Important, this is not because we haven’t seen good data or the data we expected.

On the contrary, it’s because we have seen very good data and we had the opportunity of — in a very cost effective way, given patients are in the trial, given we had EVX-01 already produced to extend the trial in — with one year at minimal cost. And this allows us to generate three-year data on this truly novel personalized cancer vaccine, which will create for a very strong data package. So, excited about that opportunity of expanding the trial and Brigitte will also be getting back to that. And with that, Brigitte, I will hand over to you to give an update from an R&D point of view.

Birgitte Rønø: Thank you, Christian. So, we have a broad R&D pipeline of AI-Immunology design cancer vaccine candidates spanning two major disease areas, cancer and infectious diseases. Today, I’ll walk you through some of our most important programs where we made significant recent progress. So, I’ll begin with our lead asset, EVX-01. This is our personalized peptide-based cancer vaccine currently in Phase 2 clinical development, as Christian just mentioned. Then, I’ll touch on the advancement in our precision cancer vaccine program targeting this novel class of tumor antigens that we have seen are shared across patients. And then, I’ll give a update on our two bacterial vaccine programs, EVX-B2 and B3, which are part of the licensing and option agreements that we have with MSD, as Christian mentioned earlier.

And finally, I will give a brief update on our cytomegalovirus or CMB vaccine program. So, EVX-01, as mentioned, is currently in Phase 2 and is being developed as a first-line treatment for advanced melanoma. And EVX-01 includes multiple patient-specific neoantigens that we have identified with our AI-Immunology platform based on the patient’s unique tumor mutational profile. And we administered EVX-01 in combination with the checkpoint inhibitor anti-PD1 from MSD with a goal of enhancing clinical efficacy. So, as Christian mentioned, we shared one-year interim data at the ESMO Congress in September and we reported an overall response rate of 69 comparing favorably to historical pembrolizumab monotherapy data. And further, we showed that a 79% of the EVX-01 vaccine new antigens induce a specific immune response in the patients, confirming the precision and predictive power of our AI-Immunology platform.

And building on this positive data and to further explore the ability of the immune response and also the clinical response, we have, as Christian mentioned, extended the Phase 2 trials one additional year to allow us to collect three-year outcome data. And notably, during this extension phase, EVX-01 will be administered as a monotherapy, allowing us to better understand the vaccine’s standalone effect. And as Christian also mentioned, this extension involves minimal additional cost as the clinical trials are already up and running and the vaccines are actually ready to be used. We are looking forward to sharing further updates on this program first at the upcoming AACR annual meeting later this month and then to present two-year efficacy data in the second half of ’25.

So, let’s turn our focus to our promising precision cancer vaccine concept. In this program, we’re using AI-Immunology to design a precision vaccine targeting these non-conventional antigens, so called ERV tumor antigens that are shared across patients. And at the Immuno-Oncology Congress in December, we presented preclinical proof-of-concept data demonstrating that our vaccine concept induced a strong antigen specific T cell responses in those immunized mice and in human immune cells, and further that we could inhibit the tumor growth in preclinical models. And as Christian also alluded to, we believe that this precision approach could allow for a broader applicability of these cancer vaccines also for patients that are less likely to respond to conventional cancer immunotherapies.

And with this very promising data enhanced, we are on track for selecting the lead candidate in the second half of 2025. So, our collaboration with MSD continues to progress as planned. In 2023, we entered into a target discovery collaboration focusing on a bacterial pathogen causing severe medical issues and where there is no existing vaccines approved. And in 2024, this collaboration was significantly expanded to include an option and license agreement for our proprietary EVX-B2 gonorrhea vaccine candidate. And we received an upfront payment of US$3.2 million with a potential US$10 million upon option exercise and further up to US$592 million per product in milestone payments. So, both EVX-B2 and B3 are advancing steadily and we remain on track for a potential option exercise in the second half of ’25.

So, we also made strong progress in our cytomegalovirus vaccine program. And CMV is a widespread viral pathogen with high global seroprevalence. It causes severe complications, especially in immunocompromised patients and also congenital infections can lead to severe birth defects and yet no approved vaccines currently exist. And with AI-Immunology, we have identified novel [B and C] (ph) cell targets, which can complement known antigens such as glycoprotein B. And this program was initially launched in partnership with ExpreS2ion Biotechnologies, as Christian mentioned, and we now have acquired full rights positioning us to drive the program forward independently. So, with these very positive data, we are on track for vaccine antigen selection in the second half of 2025.

So, just to wrap up, we’ve seen significant progress across our pipeline in both oncology and infectious diseases. And we are extremely excited about what lies ahead and I’m looking forward to updating you on our programs as they continue to advance.

Christian Kanstrup: Thank you, Birgitte. I think we can only all agree that it has been a truly exciting year across both cancer and infectious diseases and that surely makes for an exciting 2025 as well. But let’s look a little bit more at the past year and zoom in on the numbers. So, Thomas, will you take us through the financials, please?

Thomas Schmidt: Yes. Thank you, Christian and Birgitte. If we move to the financials and the financial highlights to start with, for 2024, we have recorded revenue of US$3.3 million, coming from the actions — option and license agreement with MSD, which Christian mentioned earlier. This certainly also may generate income for the future. As Birgitte also says, we are on track to the next — towards the next milestone payment in the second half of this year, plus, of course, then hopefully, in the years beyond. In 2024, we’ve also seen lower spend compared to the previous year. And this has very much been driven by the full year impact from the changes that we made back in 2023 and certainly also ongoing cost optimization and further initiatives in order to manage our cost and cash burn.

We are certainly trying to make the best use of the cash that we have at hand. And end of December 2024, cash and cash equivalents were at $6 million, which is slightly up from $5.6 million end of 2023. But of course, then also having made the effort of investing into our pipeline and platform. We’ve seen significant improvements in our equity and the financial position through the — also the recent capital market activities. And with now our existing cash position, we estimate that we have sufficient funds to fund our operating and capital expenditure requirements into mid-2026. And important to note is that, that takes us beyond the point of a potential option exercised by MSD and also beyond our two-year clinical data readout on EVX-01.

If we look at the profit and loss statement of 2024, we have had a net loss for the year of US$10.6 million. That’s corresponding to US$0.20 per basic and diluted share, which is also a slight — or improvement, so to speak, still a loss, of course, but versus 2023, where we had a loss of $22 million. Again, the loss was really driven by improvement in our recognized revenue, but certainly also, as mentioned, the reduction in our R&D and G&A expenses. Most of that came certainly from a reduced headcount, but we’ve also made changes throughout the entire organization, including management and the full year impact of that, plus, as mentioned, the general cost optimization is ongoing and has really played throughout the entire 2024. Looking a little bit ahead for 2025, Christian also mentioned that we expect that our operational cash burn is on par with 2024.

Meaning, again, also around US$14 million for the year, and that is despite that we will increase our activity level throughout the pipeline and platform elements. Balance sheet, we have certainly improved the equity throughout 2024, as mentioned, and continuing to invest in our pipeline and platform. And also, in the beginning of this year, we have further — have successful equity improvement. So, cash and cash equivalent as 27th of January were US$11.9 million, and our public offering, which closed on 31st of January, we could add a gross proceeds of US$10.8 million to — towards our cash and cash position. With that also, we are well above the Nasdaq minimum requirement on equity and shareholders’ equity, which also — again, as Christian mentioned before, also, we managed, therefore, really to be back in full compliance with the Nasdaq requirement, not only in — now in Q1, but expect to be that also for the remaining part of 2025.

Cash runway will take us to mid-2026, as already stated, and again, just to do that once again, that will further extend with a potential MSD option exercise should that happen, and assuming that exercise will happen in the second half of ’25, we will have a cash position well into 2027. And with that update on the financials, I hand it over to you, Christian.

Christian Kanstrup: Excellent. Thank you so much, Thomas. And also, thanks again to you, Birgitte. Let me just provide a few conclusive remarks. If we look at the overall picture, I would say, Evaxion has never been in a stronger position fundamentally. We have been delivering strongly on our pipeline, both from a cancer and infectious disease point of view. We are in the fortunate situation that the EVX-01 continues to deliver very strong clinical data. And we have a lot of activities within the infectious disease area where there are significant unmet needs, given many of the indications that we are targeting don’t have any approved vaccines today. So, combining that with a transformative agreement with MSD, MSD as a significant shareholder, and a solid cash position, we are in a very strong position fundamentally which provides a solid basis for 2025.

And I would say here that we are well positioned for strong ’25 execution. We have our milestones, our value triggers and our priorities locked-in. And the full organization is around that. And we are well on our way towards executing upon our 2025 priorities. This all comes from having a clear strategy with a strong focus on monetizing value through business development via both the platform and the pipeline. And that, of course, also leads to several key value catalysts coming up in 2025. We are talking about the potential option exercise from MSD, EVX-01 Phase 2 data, and, of course, a number of other important milestones coming up throughout the year. So, I think, I speak on behalf of the whole management team and the whole organization, but I can say that we are very pleased with where we are and definitely looking very much forward to 2025.

And with that, we will open for Q&A and take any questions you might have.

Q&A Session

Operator: Thank you, sir. [Operator Instructions] We are now going to proceed with our first question. And the questions come from the line of Thomas Flaten from Lake Street Capital Markets. please ask your question.

Thomas Flaten: Thank you. Good morning and good afternoon. Christian, I was just wondering, as you select new pipeline candidates, you’ve got two infectious disease and an ERV candidate that you’re going to select this year, how are you certain that those will be partnerable assets? Are these being done with input from potential partners? Is it based on literature? I’m just curious if you can take us through that decision-making process a little bit.

Christian Kanstrup: Yeah, no, thanks, Thomas. I think that’s a super relevant question, of course, because it is about creating partnerable assets, especially when you have a multi-partner approach, then you need to make sure that what you’re developing is also what people want. Of course, it all starts with, you can say, the unmet medical need and the commercial potential. That’s kind of like the first gate that you can, of course, find many areas where there’s either not a whole lot of unmet need or the commercial potential is not sufficient. So that’s the number one priority. And then, we do actually — and that’s what we are planning for both, say, the ERV-based concept, but also some of the infectious disease candidates we are working on.

We’re aiming at taking early dialogues with potential partners saying, “This is what we intend to do from a preclinical package point of view. Are there any other things you would see?” Not because we want to engage necessarily in partnering discussions now, but solicit the input from future potential partners. And I do believe that it’s very important that we get this input early. So, the preclinical program can be shaped in the right way. Of course, we have a lot of things we would like to do, but we also need to make sure that we have the package that potential partners are asking for. And Birgitte, I don’t know if you want to say a few more words on this, but this early consultation is definitely something that we have — will have focus on for, you can say, the ERV program for some of our infectious disease programs, especially when you are in areas where — which are novel and you’re breaking new ground, then it’s critical to understand what would a potential buyer want to see as early as possible.

Birgitte Rønø: Yeah. Especially for the two new infectious disease vaccine candidates that we will nominate this year, I mean, there’s, of course, the option, as you also allude to, Thomas, that it could be coming from partner discussions, but we also have done a lot of work on looking into different options. We have a long list of potential diseases to target, and we’ve done as you call it, literature analysis, trial analysis looking into the medical need, the commercial potential and feasibility. And we are definitely ready to launch a new program in this first half of [2023] (ph).

Thomas Flaten: Excellent. That’s super helpful. And with respect to ExpreS2ion Biotech handing the rights back to the CMV vaccine, can you give us some color behind that? Was the decision on their end? Was it a joint decision? Is there any capability that you’re losing in the development program with them no longer being a partner?

Christian Kanstrup: Let me first answer the overall. I mean, the decision was at their end. The way the program is structured is that either party could terminate, then the rights would go fully back to the other parties. So, you can say we have not had the cash up or anything, but have, as per contract acquired the full rights, which we are very pleased with. And then, to the capabilities, if Birgitte, you can speak to that, but I think we have definitely a good plan in place and looking forward to drive this forward on our own.

Birgitte Rønø: Yeah. So, ExpreS2ion Biotechnologies, they were doing some of the production part of the antigen. And of course, we’re looking into other solutions for getting the antigens into our lab and to test them and we have also experienced that when we have partner dialogues, it’s not always the right approach to come with a very defined modality. Partners often tend to have their own preferences, and therefore, we would also need to test our AI-Immunology identified targets on a few different vaccine modalities. So that’s the ongoing work currently. And then, we are, of course, preparing for the selection of the vaccine antigens in the second half of 2025.

Christian Kanstrup: So, you can say we, of course, have truly enjoyed the collaboration with ExpreS2ion Biotech over the past couple of years and have been very pleased with that. Then, I think this also gives us quite a unique opportunity for deploying some of the learnings that we have had over the past couple of years in many of the partnering discussions that we have had as to having some degree of flexibility in how you pack or wrap the final vaccine candidate. So, we have — as I said, we have a good plan in place and are looking forward to selecting lead antigens in the second half of the year.

Thomas Flaten: Great. Thank you for taking my questions. I appreciate it.

Operator: Thank you. [Operator Instructions] We are now going to proceed with our next question. And the questions come from the line of Swayampakula Ramakanth from HCW. Please ask your question.

Swayampakula Ramakanth: Thank you. Good afternoon, Christian and Birgitte. A couple of…

Christian Kanstrup: Hey, RK.

Swayampakula Ramakanth: Hi. A couple of quick questions. The first one being on EVX-01. So, in terms of the data coming out at AACR, what sort of data should we be expecting? And then, more importantly, as we wait for this two-year data point coming up later in the year, based on your conversations with potential collaborators to date, what amount of data do you think eventually is sufficient for a transaction? Because this is a program that’s been — that I think has produced a pretty good set of data. So, what else are people really looking for?

Birgitte Rønø: I can start. So, for the presentation at AACR, we will be presenting biomarker data and also additional T cell data from the patient. And we have already shared some of these earlier data, and we have now collected more samples and analyzed more samples from the patients. So, it will be a more in-depth biomarker presentation at AACR.

Christian Kanstrup: And then, for the, you say, data, what’s needed, I do think that the data that we are currently generating and also we’ll be generating over the remainder of the trial, that is the data that we need. What is also then important for, you can say, an eventual transaction, that’s definitely also there’s a lot of people waiting to see what are the data Merck and Moderna is going to generate going to look like. And of course, here, we were pretty encouraged seeing that Moderna was out of the TD Cowen conference earlier this year saying that they are anticipating approval in 2027. Hence, continued good progress with their personalized cancer vaccine. And I would not expect that one would need to wait until approval, but it will be interesting to see some of the early Phase 3 data from that trial.

That’s clear that people are also awaiting that. So, I would say, we have what I feel is needed from an EVX-01 point of view. And then, there’s some level of confirmation that those data would also hold up in a larger-scale later-stage Phase 3 trial, which we hopefully will see later on this year.

Swayampakula Ramakanth: Perfect. And then, regarding the ERV vaccines that you plan to work on, what types of cancers could potentially be the indications that we could use this vaccine to evaluate?

Birgitte Rønø: Yeah, really good question, RK. So, we have worked with ERV concept for quite some time now. We have looked into a lot of data from different cancer indications and have mapped out the indications where there is a high burden as we called it and that has led to the development of this precision group vaccine concept, where we can see that in specific indications that these sequences are shared across the patients. And we have a list of these cancer indications that we would like to work more on, and we will most likely also share some more information by the end of this year on possible indications to move forward with.

Swayampakula Ramakanth: Okay. And then, the last question from me. Regarding EVX-B2 and B3, would you be releasing any data ahead of submitting to MSD or as you’re submitting to MSD for their decision on exercising the option?

Christian Kanstrup: No. You could say for B2, MSD is doing some confirmatory work on the data that we have generated. Hence, we will not be releasing more data there. B3, that’s the finalization of the current — of the work plan that we agreed in 2023. That’s being completed. And the major part of work there is with MSD as well.

Swayampakula Ramakanth: Okay. Perfect. Thank you, both. Thanks for taking all my questions.

Christian Kanstrup: You’re welcome. Good talking to you.

Operator: [Operator Instructions] We have no further questions at the moment registered. So, I will now hand back to Christian Kanstrup for closing remarks.

Christian Kanstrup: Thank you so much. And I just want to wrap up by saying thank you to all of you for listening in, and thank you for the questions as well. As already said, 2024 was a very exciting year, creating a strong foundation for 2025. We are now in execution mode and we’ll be focusing on delivering on our key milestones for the year. So, we are definitely looking very much forward to 2025. And we’ll, of course, make sure to keep you all up to date on all recent events with Evaxion. So, once again, thank you so much for taking the time for listening in, and we will stay in touch.

Operator: This concludes today’s conference call. Thank you all for participating. You may now disconnect your lines. Thank you, and have a good day.